French Guidelines For the Emergency Management of Headaches

Moisset, Xavier; Mawet, Jérôme; Guégan-Massardier, Évelyne; Bozzolo, E.; Gilard, Vianney; Tollard, É.; Feraud, Thierry; Noëlle, Bénédicte; Rondet, Claire; Donnet, Anne

doi:10.1016/j.neurol.2016.06.005

Cited by 19 publications

(19 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consecutively, angiography, which was the gold standard for SAH and aneurysm diagnosis, has gradually been discarded. Lumbar puncture is limited to cases with a severe headache and clear CT-scan 31 . Care standards for patients suffering from NTIB have also changed over the last 40 years.…”

Section: Discussionmentioning

confidence: 99%

Tranexamic acid in non-traumatic intracranial bleeding: a systematic review and meta-analysis

Bouillon‐Minois

Croizier

Baker

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Non-traumatic intracranial bleeding (NTIB), comprising subarachnoid hemorrhage (SAH) and intra-cranial bleeding (ICH) is a significant public health concern. Tranexamic acid (TXA) is a promising treatment with benefits yet to be fully demonstrated. We conducted a systematic review and meta-analysis on the impact of TXA on mortality in NTIB. We searched the PubMed, Cochrane Library, Google Scholar and ScienceDirect databases for studies reporting mortality data following the use of TXA in NTIB for comparisons with a control group. We computed random-effect meta-analysis on estimates of risk and sensitivity analyses. We computed meta-regression to examine the putative effects of the severity of NTIB, sociodemographic data (age, sex), and publication date. Among potentially 10,008 articles, we included 15 studies representing a total of 4883 patients: 2455 receiving TXA and 2428 controls; 1110 died (23%) during the follow-up. The meta-analysis demonstrated a potential of 22% decrease in mortality for patients treated by TXA (RR = 0.78, 95%CI 0.58–0.98, p = 0.002). Meta-regression did not demonstrate any influence of the severity of NTIB, age, sex, length of treatment or date of publication. Sensitivity analyses confirmed benefits of TXA on mortality. TXA appears to be a therapeutic option to reduce non-traumatic intracranial bleeding mortality, particularly in patients with SAH.

show abstract

Section: Discussionmentioning

confidence: 99%

Tranexamic acid in non-traumatic intracranial bleeding: a systematic review and meta-analysis

Bouillon‐Minois

Croizier

Baker

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…After screening for eligibility, 461 titles and abstracts were eliminated. Of the 23 full-text articles, two were not eligible, because the CPG was irretrievable ( n = 1), or the CPG was a summary ( n = 1), leaving 21 CPGs eligible for review [ 28 – 48 ]; thirteen CPGs made CAM recommendations [ 28 , 29 , 32 , 34 – 36 , 38 – 41 , 43 – 45 , 48 ], two CPGs made mention of CAM but provided no recommendations [ 33 , 48 ], and the final six CPGs made no mention nor recommendations pertaining to CAM [ 30 , 31 , 37 , 42 , 46 , 47 ]. The citations associated with the excluded full-text items are provided in Supplementary File 3 .…”

Section: Resultsmentioning

confidence: 99%

“…Of the remaining 6 CPGs, 1 was rated by the two appraisers as “No” and “Yes” respectively [ 34 ], while 5 CPGs were rated as “Yes” and “Yes with modifications” respectively [ 28 , 32 , 36 , 39 , 43 ].…”

Section: Resultsmentioning

confidence: 99%

Headache and migraine clinical practice guidelines: a systematic review and assessment of complementary and alternative medicine recommendations

Hanna

2021

BMC Complement Med Ther

View full text Add to dashboard Cite

Background Globally, 3 billion people suffer from either migraine or tension-type headache disorder over their lifetime. Approximately 50% of American adults suffering from headache or migraine have used complementary and alternative medicine (CAM), however, the quality and quantity of recommendations associated with such therapies across clinical practice guidelines (CPGs) for the treatment and/or management of these conditions are unknown. The purpose of this study was to identify the quantity and assess the quality of such CAM recommendations. Methods MEDLINE, EMBASE and CINAHL were systematically searched from 2009 to April 2020; the Guidelines International Network and the National Center for Complementary and Integrative Health websites were also searched for eligible CPGs. CPGs were included if they provided any therapy recommendations. Eligible CPGs included those written for adult patients with headache and migraine; CPGs containing CAM recommendations were assessed twice for quality using the AGREE II instrument, once for the overall CPG and once for the CAM sections. Results Of 486 unique search results, 21 CPGs were eligible and quality assessed; fifteen CPGs mentioned CAM, of which 13 CPGs made CAM recommendations. The overall CPG assessment yielded higher scaled domain percentages than the CAM section across all domains. The results from highest to lowest were as follows (overall, CAM): clarity of presentation (66.7% vs. 50.0%), scope and purpose (63.9% vs. 61.1%), stakeholder involvement (22.2% vs. 13.9%), rigour of development (13.5% vs. 9.4%), applicability (6.3% vs. 0.0%), and editorial independence (0.0% vs. 0.0%). Conclusions Of the eligible CPGs, the CAM sections were of lower quality compared to the overall recommendations across all domains of the AGREE II instrument. CPGs that scored well could serve as a framework for discussion between patients and healthcare professionals regarding use of CAM therapies in the context of headache and migraine.

show abstract

“…It is also thought that prochlorperazine provides antiemetics effect on the chemoreceptor trigger zone . The use of prochlorperazine to treat migraine headaches has been widely accepted in the last 3 decades and strongly recommended by several guidelines …”

Section: Discussionmentioning

confidence: 99%

Buccally absorbed vs intravenous prochlorperazine for treatment of migraines headaches

et al. 2019

View full text Add to dashboard Cite

Objective To compare the efficacy of buccally absorbed prochlorperazine (BAP) to intravenous prochlorperazine (IVP) for the abortive treatment of migraine headaches. Methods Randomized double‐blind trial. Eighty subjects aged 18‐65 presenting with migraines to the ED of a safety‐net, urban hospital. Subjects were randomized to receive either 6 mg BAP plus 2.25 mL saline IV placebo or 10 mg IVP and buccally absorbed saccharine pill placebo. A 100 mm visual analog scale (VAS) was used to assess pain, nausea, and sedation. Comparisons between groups were analyzed by the Mann‐Whitney U test or Fisher’s exact test. Results Eighty subjects were recruited from November 2016 to December 2017; 79 completed the study. Demographics: 60 women and 19 men with a mean age of 38 ± 12.2 years. Initial mean VAS pain scores were similar between groups (BAP: 78.5 ± 19.9 mm vs IVP: 76.9 ± 19.5 mm). The improvement in mean VAS pain scores over 60 minutes for the BAP group was not significantly different from the IVP group (−54.9 ± 29.7 mm vs −66.7 ± 23.2 mm, respectively; P = 0.08). No significant differences were found in rates of nausea or sedation. Nine subjects in the BAP group required rescue treatment compared to 1 in the IVP group. Five subjects reported symptoms consistent with akathisia in the IVP group while no adverse effects were reported in the BAP group. Conclusion Buccally absorbed prochlorperazine (BAP) is an effective, non‐invasive treatment for migraine headaches when compared to intravenous prochlorperazine (IVP).

show abstract

French Guidelines For the Emergency Management of Headaches

Cited by 19 publications

References 47 publications

Tranexamic acid in non-traumatic intracranial bleeding: a systematic review and meta-analysis

Tranexamic acid in non-traumatic intracranial bleeding: a systematic review and meta-analysis

Headache and migraine clinical practice guidelines: a systematic review and assessment of complementary and alternative medicine recommendations

Buccally absorbed vs intravenous prochlorperazine for treatment of migraines headaches

Contact Info

Product

Resources

About